Chiesi webinar: prescribing information not readable/long enough and Trimbow described as “safe” (AUTH/3516/5/21)

📊

Key facts

⌄

Case	AUTH/3516/5/21
Complainant	Health professional (contactable)
Company	Chiesi Limited
Material	Webinar: “Session 3: Evolving Developments in the Management of asthma”
Webinar date	25 May 2021
Complaint received	26 May 2021
Case completed	8 February 2022
Applicable Code year	2019
Breach clauses	Clause 4.1; Clause 7.9
No breach clauses (listed)	Clause(s) 2, 4.1, 4.8, 7.2, 7.4, 9.1
Sanctions	Undertaking received
Appeal	No appeal
Products referenced	Trimbow; Fostair
Job code/date noted by Panel	UK-TRI-2100147; April 2021

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

A health professional complained about a Chiesi-organised webinar (25 May 2021) titled “Session 3: Evolving Developments in the Management of asthma”.
Concerns included: prescribing information (PI) not present/legible; rounding of clinical data (“almost”, “approx”); “extrafine/fine particle” implications for lung deposition; missing approval code/date; comments about switching SABA devices (“low hanging fruit”); “recipe for disaster” language about mixing inhaler devices; Q&A comments encouraging guideline listing; and Trimbow being called “safe”.
The Panel accepted the invitation itself did not mention any Chiesi medicine and was not promotional.
The Panel reviewed Chiesi’s webinar recording and found the PI slides were difficult to read (slightly blurred) and displayed for too short a time to be readable.
In the Q&A, the presenter referred to Trimbow as “safe medicines” in a way the Panel considered related to Trimbow (not just the class), triggering a breach.

⚖️

⌄

Breach found: Clause 4.1 (prescribing information in the webinar not sufficiently clear/long enough to read).
Breach found: Clause 7.9 (use of the word “safe” in relation to Trimbow).
No breach: Clause 4.1 (invitation); Clause 7.2 (terminology/rounding); Clauses 7.2 and 7.4 (extrafine/lung deposition substantiation); Clauses 4.8 and 9.1 (date of preparation/approval code issue); Clauses 2, 7.2 and 9.1 (SABA/carbon footprint comments); Clauses 2, 7.2, 7.4 and 9.1 (device-type “recipe for disaster” and guideline discussion/scaremongering allegations).
No breach of Clause 2 was ruled.
No appeal.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access